Jackson Square Capital LLC increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 256.2% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 8,011 shares of the biopharmaceutical company's stock after buying an additional 5,762 shares during the quarter. Jackson Square Capital LLC's holdings in Gilead Sciences were worth $898,000 as of its most recent filing with the SEC.
A number of other large investors have also modified their holdings of GILD. Annis Gardner Whiting Capital Advisors LLC boosted its holdings in Gilead Sciences by 158.8% in the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 216 shares during the last quarter. Morton Brown Family Wealth LLC purchased a new position in Gilead Sciences in the fourth quarter valued at about $35,000. Whipplewood Advisors LLC purchased a new position in Gilead Sciences in the fourth quarter valued at about $35,000. Synergy Investment Management LLC purchased a new position in Gilead Sciences in the fourth quarter valued at about $40,000. Finally, Lee Danner & Bass Inc. purchased a new position in Gilead Sciences in the fourth quarter valued at about $41,000. Institutional investors and hedge funds own 83.67% of the company's stock.
Insider Transactions at Gilead Sciences
In other news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total value of $3,010,560.00. Following the transaction, the insider now directly owns 121,152 shares in the company, valued at approximately $13,026,263.04. The trade was a 18.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction that occurred on Friday, May 30th. The shares were sold at an average price of $110.42, for a total value of $1,104,200.00. Following the completion of the transaction, the chief executive officer now directly owns 620,268 shares of the company's stock, valued at approximately $68,489,992.56. This trade represents a 1.59% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 43,000 shares of company stock worth $4,630,310. Company insiders own 0.27% of the company's stock.
Gilead Sciences Stock Down 1.8%
GILD traded down $2.07 during trading on Friday, reaching $109.98. 8,148,740 shares of the stock traded hands, compared to its average volume of 7,744,306. The stock has a market cap of $136.81 billion, a price-to-earnings ratio of 297.24, a price-to-earnings-growth ratio of 0.71 and a beta of 0.29. Gilead Sciences, Inc. has a fifty-two week low of $62.69 and a fifty-two week high of $119.96. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The stock's 50-day simple moving average is $105.67 and its two-hundred day simple moving average is $102.26.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The firm had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. During the same quarter last year, the firm earned ($1.32) earnings per share. The business's revenue for the quarter was down .3% on a year-over-year basis. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.
Gilead Sciences Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be paid a $0.79 dividend. The ex-dividend date is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.87%. Gilead Sciences's payout ratio is presently 66.53%.
Analyst Ratings Changes
Several brokerages recently issued reports on GILD. Morgan Stanley raised their price target on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a "hold" rating to a "buy" rating and raised their target price for the company from $80.00 to $120.00 in a research report on Tuesday, February 18th. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. JPMorgan Chase & Co. raised their target price on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. Finally, Bank of America lifted their price target on Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Nine analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and an average target price of $110.55.
Read Our Latest Stock Report on Gilead Sciences
Gilead Sciences Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
See Also
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
